Madam,
We read with great interest the papers by Dizdar et al. and by O'Connell et al. about the use of palivizumab during a respiratory syncytial virus (RSV) outbreak in neonatal intensive care units (NICUs), suggesting that palivizumab administration might have a role in controlling RSV outbreak and recommended early administration of palivizumab to terminate transmission as quickly as possible.1, 2 We recently experienced a similar outbreak in our NICU, and controlled it according to the suggestions made in this paper.
There were ten preterm (median gestational age: 29.3 weeks; range: 26.2–32 weeks; birth weight: 848–1520 g), two late preterm (>35 weeks' gestational age) and four term infants in the NICU when two term newborns with bronchopneumonia and respiratory insufficiency were admitted to the NICU isolation unit between 29 February 2012 and 12 March 2012. Polymerase chain reaction (PCR) screening including RSV (A, B), coronavirus (A, B, C, D, E, OC43, HKU1), parainfluenza (1, 2, 3, 4), rhinovirus (A, B, C), influenza (A, B), bocavirus (1, 2, 3, 4), metapneumovirus and enterovirus, revealed RSV type B infection in these two patients. Although patients with RSV were cared for in separate isolation rooms, another preterm infant who had recovered from respiratory distress syndrome developed further respiratory distress after a week. Nasopharyngeal secretions obtained from this infant also revealed RSV type B infection and we decided to screen the remaining 15 infants for RSV. None of the asymptomatic patients was RSV PCR positive. In order to prevent an escalating NICU outbreak, palivizumab prophylaxis was administered to nine preterm infants, all of whom were <32 weeks of gestational age at birth, and one patient who had a congenital heart disease at a dosage of 15 mg/kg, in addition to strict contact precautions. Patients with RSV bronchiolitis recovered after about 10 days and we did not observe any additional cases with RSV.
RSV infection was brought into the NICU by two patients with RSV bronchiolitis. Following this, one preterm patient, who was recovering from respiratory distress, developed RSV bronchiolitis. As NICUs like ours embrace a family-centred model for patient care, greater difficulties complying with effective infection control measures may emerge.3 We agree with Dizdar et al. and O'Connell et al. that palivizumab prophylaxis may have a role in the control of RSV epidemics in the NICU.1, 2 If we had not given palivizumab prophylaxis after detection of index cases, a larger RSV outbreak might have occurred in our NICU. After a few small RSV NICU outbreaks in Turkey, the Turkish Neonatal Society now recommends RSV prophylaxis for premature infants in the NICU who are already candidates for the prophylaxis programme as outpatients when at least three RSV-positive patients are present in the NICU. This recommendation is similar to the one reported by the Spanish Neonatal Society which suggests palivizumab prophylaxis for preterm infants and newborns with haemodynamically significant congenital heart disease when such outbreaks occur.4
Conflict of interest statement
None declared.
Funding sources
None.
References
- 1.Dizdar E.A., Aydemir C., Erdeve O. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit. J Hosp Infect. 2010;75:292–294. doi: 10.1016/j.jhin.2010.01.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.O'Connell K., Boo T.W., Keady D. Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction. J Hosp Infect. 2011;77:338–342. doi: 10.1016/j.jhin.2010.12.012. [DOI] [PubMed] [Google Scholar]
- 3.Heerens A.T., Marshall D.D., Bose C.L. Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit. J Perinatol. 2002;22:306–307. doi: 10.1038/sj.jp.7210696. [DOI] [PubMed] [Google Scholar]
- 4.Figueras Aloy J., Quero J., Doménech E. Comité de Estándares de la Sociedad Española de Neonatología. Recommendations for the prevention of respiratory syncytial virus infection. An Pediatr (Barc) 2005;63:357–362. doi: 10.1157/13079818. [DOI] [PubMed] [Google Scholar]